Serous tubal intraepithelial carcinoma (STIC) – clinical impact
and management

J 2016

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

WEINBERGER, Vít; Markéta BEDNAŘÍKOVÁ; David CIBULA a Michal ZIKAN

Základní údaje

Originální název

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Autoři

WEINBERGER, Vít; Markéta BEDNAŘÍKOVÁ; David CIBULA a Michal ZIKAN

Vydání

Expert Review of Anticancer Therapy, Abingdon, Taylor & Francis LTD, 2016, 1473-7140

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.212

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00091587

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

BRCA mutation; Fallopian tube; Ovarian carcinoma; Risk reducing salpingooophorectomy; Serous tubal intraepithelial carcinoma

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 1. 2017 12:02, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Introduction Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent followup procedure in women with an isolated STIC. Expert commentary Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer.

Citovat

WEINBERGER, Vít; Markéta BEDNAŘÍKOVÁ; David CIBULA a Michal ZIKAN. Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. Expert Review of Anticancer Therapy. Abingdon: Taylor & Francis LTD, 2016, roč. 16, č. 12, s. 1311-1321. ISSN 1473-7140. Dostupné z: https://doi.org/10.1080/14737140.2016.1247699.

@article{1359770,
   author = {Weinberger, Vít and Bednaříková, Markéta and Cibula, David and Zikan, Michal},
   article_location = {Abingdon},
   article_number = {12},
   doi = {https://doi.org/10.1080/14737140.2016.1247699},
   keywords = {BRCA mutation; Fallopian tube; Ovarian carcinoma; Risk reducing salpingooophorectomy; Serous tubal intraepithelial carcinoma},
   language = {eng},
   issn = {1473-7140},
   journal = {Expert Review of Anticancer Therapy},
   title = {Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management},
   volume = {16},
   year = {2016}
}

TY  - JOUR
ID  - 1359770
AU  - Weinberger, Vít - Bednaříková, Markéta - Cibula, David - Zikan, Michal
PY  - 2016
TI  - Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management
JF  - Expert Review of Anticancer Therapy
VL  - 16
IS  - 12
SP  - 1311-1321
EP  - 1311-1321
PB  - Taylor & Francis LTD
SN  - 14737140
KW  - BRCA mutation
KW  - Fallopian tube
KW  - Ovarian carcinoma
KW  - Risk reducing salpingooophorectomy
KW  - Serous tubal intraepithelial carcinoma
N2  - Introduction Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent followup procedure in women with an isolated STIC. Expert commentary Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer.
ER  -

WEINBERGER, Vít; Markéta BEDNAŘÍKOVÁ; David CIBULA a Michal ZIKAN. Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. \textit{Expert Review of Anticancer Therapy}. Abingdon: Taylor \&{} Francis LTD, 2016, roč.~16, č.~12, s.~1311-1321. ISSN~1473-7140. Dostupné z: https://doi.org/10.1080/14737140.2016.1247699.

Přehled o publikaci